Results 181 to 190 of about 8,795,233 (257)

Longitudinal Quality of Life After Total Neoadjuvant Therapy for Rectal Cancer in the SHORT-FOX Trial.

JAMA Netw Open
Arnow KD, Brown E, Pollom EL, Holden T, Shearer J, Morris AM.   +5 more
europepmc   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

Four-Year Survival Outcomes of Personalized Total Neoadjuvant Therapy Versus Chemotherapy During the 'Wait Period' Versus Standard Chemoradiotherapy for Locally Advanced Rectal Cancer. [PDF]

J Gastrointest Cancer
Bedrikovetski S, Bunjo Z, Murshed I, Moore JW, Sammour T.   +4 more
europepmc   +1 more source

Value of Axillary Palpation and Ultrasound, and Axillary Recurrence in Male Breast Cancer: Results of the Registry Study

International Journal of Cancer, EarlyView.
ABSTRACT Clinical and sonographic examination of breasts and axillae is standard in breast cancer (BC) care. The aim of this study is to highlight the value of axillary ultrasound in identifying axillary recurrences in male BC, which is still little considered in the literature.
Monika Graeser, Susen Bothin, Oleg Gluz, Mathias Warm, Atanas Ignatov, Holm Eggemann   +5 more
wiley   +1 more source

Personalized Radiotherapy and Treatment Strategies for Locally Advanced Rectal Cancer: Early Outcomes of a Tailor-Made Total Neoadjuvant Therapy Protocol. [PDF]

Cancers (Basel)
Ogura A, Murata Y, Sato Y, Umeda S, Tsutsuyama M, Ebata T, Kanda M.   +6 more
europepmc   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

Pelvic MRI Following Total Neoadjuvant Therapy for Rectal Cancer Poorly Predicts a Complete Clinical Response. [PDF]

J Surg Oncol
Suss NR, Johnson R, Olortegui KS, Liauw SL, Shergill A, Polite B, Shogan BD.   +6 more
europepmc   +1 more source

Perioperative Rehabilitation and Initiation of Adjuvant Chemotherapy in Resected Non‐Small Cell Lung Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant chemotherapy can improve outcomes for patients who have undergone lung cancer resection, and perioperative rehabilitation may help maintain the physical condition necessary to receive adjuvant chemotherapy. This observational cohort study investigated the impact of perioperative rehabilitation on the administration of postoperative ...
Shinkichi Takamori, Tateaki Naito, Nobuko Konishi, Tetsuya Tsuji, Ikumi Takashima, Ryotaro Ide, Masakazu Fujiwara, Atsuki Yamamoto, Yusuke Takagi, Mizue Ogi, Shinya Uematsu, Hiroshi Kitagawa, Koichi Takayama   +12 more
wiley   +1 more source

Magnetic Resonance Imaging After Total Neoadjuvant Therapy in Rectal Cancer: Treatment-Oriented Response Assessment and Reporting for Watch-and-Wait Management. [PDF]

Korean J Radiol
Kim HY, Jang JK, Gollub MJ.
europepmc   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source